Computationally Derived Spatial Immune Signature Identifies Trastuzumab Responders in HER2+ Breast Cancer: NSABP B41 Clinical Trial Validation

20260 citationsJournal Articlehybrid Open Access

Authors

Satvika Bharadwaj · The Wallace H. Coulter Department of Biomedical Engineering

Germán Corredor · Emory University

Hilmi Al-Shakhshir · Atlanta Medical Center

Sebastian Medina · The Wallace H. Coulter Department of Biomedical Engineering

Sahar N. Almahfouz · Emory University

Rohan Dhamdhere · The Wallace H. Coulter Department of Biomedical Engineering

Tilak Pathak

Abstract

DeSTIL identifies a subset of HER2+ patients who derive greater benefit from trastuzumab. These findings support the potential of computationally derived immune architecture to inform selection of standard HER2-targeted therapies.

Topics & Keywords

HER2/EGFR in Cancer Research Cancer Immunotherapy and Biomarkers Monoclonal and Polyclonal Antibodies Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-25-4185

Field-Weighted Citation Impact: 0.00